Open AccessAbsorbed dose assessment of177Lu-zoledronate and177Lu-EDTMP for human based on biodistribution data in rats
Author(s) -
Hassan Yousefnia,
Samaneh Zolghadri,
Amir Reza Jalilian
Publication year - 2015
Publication title -
journal of medical physics/journal of medical physics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.292
H-Index - 24
eISSN - 1998-3913
pISSN - 0971-6203
DOI - 10.4103/0971-6203.158694
Subject(s) - biodistribution , dosimetry , nuclear medicine , medicine , radiochemistry , bone pain , bisphosphonate , chemistry , osteoporosis , surgery , biochemistry , in vitro
Over the past few decades, several bone-seeking radiopharmaceuticals including various bisphosphonate ligands and β-emitting radionuclides have been developed for bone pain palliation. Recently, (177)Lu was successfully labeled with zoledronic acid ((177)Lu-ZLD) as a new generation potential bisphosphonate and demonstrated significant accumulation in bone tissue. In this work, the absorbed dose to each organ of human for (177)Lu-ZLD and (177)Lu-ethylenediaminetetramethylene phosphonic acid ((177)Lu-EDTMP;as the only clinically bone pain palliation agent) was investigated based on biodistribution data in rats by medical internal radiation dosimetry (MIRD) method. (177)Lu-ZLD and (177)Lu-EDTMP were prepared in high radiochemical purity (>99%, instant thin layer chromatography (ITLC)) at the optimized condition. The biodistribution of the complexes demonstrated fast blood clearance and major accumulation in the bone tissue. The highest absorbed dose for both (177)Lu-ZLD and (177)Lu-EDTMP is observed in trabecular bone surface with 12.173 and 10.019 mSv/MBq, respectively. The results showed that (177)Lu-ZLD has better characteristics compared to (177)Lu-EDTMP and can be a good candidate for bone pain palliation.